Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -146.1%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11M | $80M | $15M | $46M | $47M | $59M | $21M | $12M | $6M | $22M | $37M |
| Enterprise Value | $11M | $80M | $9M | $20M | $-19610057 | $-28340759 | $2M | $5M | $6M | $23M | $31M |
| P/E Ratio → | -0.42 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.52 | 3.64 | 0.59 | 3.35 | 8.60 | 9.88 | 4.74 | 2.55 | 0.98 | 2.87 | 6.28 |
| P/B Ratio | 9.85 | 9.55 | 0.80 | 1.00 | 0.70 | 0.66 | 0.96 | 1.15 | 3.29 | 6.00 | 4.47 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.62 | 0.35 | 1.47 | -3.56 | -4.75 | 0.46 | 1.05 | 0.85 | 2.97 | 5.32 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.3% | 38.3% | 32.0% | 32.1% | 34.6% | 48.7% | 49.8% | 55.9% | 43.2% | 40.0% | 12.5% |
| Operating Margin | -76.7% | -76.7% | -76.2% | -170.4% | -346.6% | -212.1% | -273.3% | -288.3% | -293.6% | -283.7% | -518.7% |
| Net Profit Margin | -90.4% | -90.4% | -112.8% | -159.8% | -355.1% | -213.5% | -295.4% | -319.1% | -331.2% | -318.8% | -553.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -146.1% | -146.1% | -88.6% | -38.6% | -24.8% | -22.9% | -79.7% | -244.4% | -767.0% | -413.1% | -393.5% |
| ROA | -74.6% | -74.6% | -61.8% | -32.2% | -23.2% | -20.7% | -49.5% | -79.1% | -114.6% | -90.5% | -102.3% |
| ROIC | -122.9% | -122.9% | -88.6% | -164.8% | -876.0% | -371.3% | -279.1% | -465.2% | -516.7% | -465.5% | -879.8% |
| ROCE | -108.5% | -108.5% | -54.6% | -39.1% | -23.9% | -22.2% | -63.8% | -118.1% | -169.2% | -135.3% | -157.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 0.05 | 0.04 | 0.01 | 0.01 | 0.07 | 0.83 | 4.47 | 4.14 | 2.18 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.07 | -0.32 | -0.56 | -0.98 | -0.98 | -0.86 | -0.68 | -0.44 | 0.21 | -0.69 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -57.26 | -57.26 | -224.77 | -1180.60 | -867.27 | -504.68 | -12.92 | -9.18 | -7.95 | -8.93 | -15.19 |
Net cash position: cash ($2M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.31 | 1.31 | 2.08 | 3.33 | 15.16 | 22.91 | 5.41 | 2.07 | 2.46 | 2.15 | 2.38 |
| Quick Ratio | 0.84 | 0.84 | 1.43 | 2.85 | 14.55 | 22.17 | 4.65 | 1.74 | 1.97 | 1.71 | 2.12 |
| Cash Ratio | 0.18 | 0.18 | 0.68 | 2.38 | 14.20 | 21.88 | 4.36 | 1.60 | 1.77 | 1.50 | 1.91 |
| Asset Turnover | — | 0.96 | 0.84 | 0.22 | 0.07 | 0.06 | 0.16 | 0.20 | 0.44 | 0.34 | 0.18 |
| Inventory Turnover | 2.37 | 2.37 | 2.60 | 1.66 | 1.23 | 1.02 | 0.62 | 0.64 | 1.42 | 1.09 | 1.57 |
| Days Sales Outstanding | — | 101.68 | 85.39 | 82.20 | 68.62 | 35.79 | 56.83 | 59.47 | 42.27 | 51.93 | 77.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 2.1% | 5.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 2.1% | 5.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $723983 | $710657 | $742308 | $570434 | $187603 | $68583 | $17523 | $9622 | $6273 |
Imminent liquidity and dilution
According to current market data, Lifeward trades at a price-to-sales ratio of 0.53, which, when compared to the broader medical robotics peer group, suggests that investors are heavily discounting the company's future revenue potential due to persistent operating losses and the absence of a clear path to profitability.
The lack of a positive P/E ratio and the absence of meaningful EBITDA multiples indicate that the market is currently valuing Lifeward as a speculative option on future reimbursement success rather than a going concern. This valuation level implies that the market expects significant further dilution, as the current price fails to account for the capital intensity required to sustain the business.
As reported in recent financial statements, Lifeward's ROIC has remained consistently negative, reaching -134.8% in 2026Q1, which indicates that the company is currently destroying shareholder capital rather than compounding it through its core operations or recent strategic acquisitions.
The persistent decay in return on invested capital suggests that the company's heavy investment in R&D and specialized sales infrastructure has failed to generate sufficient incremental returns. Investors should monitor whether the integration of AlterG can eventually improve these metrics, though current trends suggest a structural inability to achieve positive returns on capital.
Based on the provided quarterly data, Lifeward's cash conversion cycle has fluctuated significantly, peaking at 162 days in 2025Q1, which highlights the inherent difficulty in managing inventory and receivables within a business model dependent on complex, multi-stage insurance reimbursement processes.
The high days sales outstanding (DSO) of 135 days in 2026Q1 suggests that the company faces substantial delays in converting sales into actual cash, which exacerbates its liquidity constraints. This inefficiency appears to be a structural hurdle that limits the company's ability to self-fund its operations.
As reported in recent filings, Lifeward's debt-to-equity ratio has surged to 1.40 in 2026Q1, a significant increase from historical levels, which indicates that the company is increasingly reliant on debt financing to bridge the gap left by its persistent operating cash flow deficits.
The spike in leverage, combined with a negative interest coverage ratio, suggests that the company's ability to service its debt is becoming increasingly precarious. This trend warrants close investigation, as it may signal an approaching need for a dilutive equity raise to avoid a potential default scenario.
Investors frequently misapply top-line revenue growth as a proxy for business health, yet as evidenced by Lifeward's -14.14% year-over-year revenue decline, this metric obscures the underlying volatility of the company's transition from a pure-play exoskeleton firm to a diversified rehabilitation platform.
Focusing on revenue growth alone ignores the critical importance of the 'Lead-to-Insurance-Approval Conversion Rate,' which is the true driver of long-term value for this business model. Analysts should instead prioritize cash burn and reimbursement success rates, as these metrics provide a more accurate assessment of the company's viability than raw revenue figures.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LFWD stock.
Lifeward Ltd.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Lifeward Ltd.'s return on equity (ROE) is -146.1%. The historical average is -161.3%.
Based on historical data, Lifeward Ltd. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Lifeward Ltd. has 38.3% gross margin and -76.7% operating margin.